Active ingredientObicetrapibCat. No. P-O002-001CAS 866399-87-3Family · Pharmaceutical analytical standards
Obicetrapib
An inhibitor of CETP, the protein that transfers cholesterol esters between blood lipoproteins: it lowers LDL cholesterol and was approved in the European Union in September 2026, alone or together with ezetimibe. This family brings together the active ingredient.
Did you know?In clinical studies, compared with placebo, it lowered LDL cholesterol by up to 51% and raised HDL cholesterol by up to 165%.
Go to the active ingredient →Active ingredientObicetrapibCat. No. P-O002-001CAS 866399-87-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.